Thirdly, the lack of prognostic value of anti-DSG-2 antibodies in our ARVC patients may have been due to the relatively small sample size and rate of adverse events observed in our cohort; further studies are needed to elucidate the role of anti-DSG-2 antibodies in larger prospective ARVC cohorts. The gene discussed is DSG2; the disease is arrhythmogenic right ventricular cardiomyopathy.